Skip to main content

Crohn's Disease News

Research Review
04/02/2026
Jessica Garlewicz
Post-hoc analysis shows that endoscopic responses to subcutaneous infliximab were observed across all intestinal segments, including the terminal ileum.
Post-hoc analysis shows that endoscopic responses to subcutaneous infliximab were observed across all intestinal segments, including the terminal ileum.
Post-hoc analysis shows that...
04/02/2026
Advances in Inflammatory Bowel Disease Network
Research Review
04/02/2026
Jessica Garlewicz
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of...
04/02/2026
Advances in Inflammatory Bowel Disease Network
Research Review
04/02/2026
Jessica Garlewicz
Isolated ileal Crohn’s has proved difficult to for most currently available advanced therapies, researchers found.
Isolated ileal Crohn’s has proved difficult to for most currently available advanced therapies, researchers found.
Isolated ileal Crohn’s has...
04/02/2026
AIBD NP/PA Institute
Research Summary
03/18/2026
Jessica Garlewicz
Risk stratification and postoperative prophylaxis are important for patients who have undergone segmental colectomy for Crohn’s disease, researchers reported.
Risk stratification and postoperative prophylaxis are important for patients who have undergone segmental colectomy for Crohn’s disease, researchers reported.
Risk stratification and...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
03/18/2026
Jessica Garlewicz
The findings of a recent claims analysis highlight gaps between risk burden and treatment patterns in real-world practice.
The findings of a recent claims analysis highlight gaps between risk burden and treatment patterns in real-world practice.
The findings of a recent claims...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
01/14/2026
Jessica Garlewicz
Endoscopic response, transmural remission, and transmural response rates showed no significant differences between treatment groups at either assessment window.
Endoscopic response, transmural remission, and transmural response rates showed no significant differences between treatment groups at either assessment window.
Endoscopic response, transmural...
01/14/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/18/2025
Jessica Garlewicz
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network